臨床試験用品市場 – 2030年までの世界予測

Report Overview

The global Clinical Trial Supplies market is anticipated to reach USD 8.18 billion in 2030 from USD 5.34 billion in 2025, with a significant CAGR of 8.9%.

世界の臨床試験用品市場は、2025年の53億4,000万米ドルから2030年には81億8,000万米ドルに達し、8.9%という大幅なCAGRで成長すると予想されています。

The clinical trial supplies market is driven by the increasing volume and complexity of global clinical trials, the rise of personalized medicine, and stringent regulatory requirements. Decentralized and adaptive trial designs are fueling demand for specialized supply chain solutions, including direct-to-patient logistics and just-in-time inventory management. Growing biologics and cell & gene therapy trials necessitate temperature-controlled storage and distribution. Digitalization, such as IoT-enabled tracking and AI-driven demand forecasting, is optimizing supply chain efficiency.

臨床試験用品市場は、世界的な臨床試験の件数と複雑さの増加、個別化医療の台頭、厳格な規制要件によって推進されています。分散型で適応型の試験設計により、患者への直接物流やジャストインタイムの在庫管理など、特殊なサプライ チェーンソリューションの需要が高まっています。生物製剤や細胞・遺伝子治療の試験の増加には、温度管理された保管と配送が必要です。IoT 対応の追跡や AI 駆動型の需要予測などのデジタル化により、サプライ チェーンの効率が最適化されています。

“Logistics & Distribution Services dominated the service segment”

Based on services the market is segmented into Logistics & distribution, storage & retention, packaging, labeling and blinding, manufacturing, comparator sourcing and other services. Logistics & Distribution Services dominated the market in 2024 and Sourcing & Procurement Services is anticipated to grow at higher CAGR owing to increasing complexity of trial protocols, the globalization of clinical studies, and the rising demand for cost-effective supply chain management. Sponsors and CROs are outsourcing procurement to specialized vendors to ensure regulatory compliance, mitigate supply risks, and optimize inventory management.

“Phase III segment dominate the phase segment in 2024”

The phase segment is further divided into Phase I, Phase II, Phase III, Phase IV and Phase BA/BE. The rise of biologics, cell & gene therapies, and personalized medicine has further intensified the demand for specialized storage and transportation solutions in Phase III trials. The Phase II segment is anticipated to grow at a significant CAGR during the forecast period in the Clinical Trial Supplies Market owing to the rising focus on innovative therapies, including biologics, gene therapies, and targeted drugs, has led to a surge in Phase II trials, which assess the efficacy and optimal dosing of investigational treatments.

“Pharmaceutical & Biotechnology Companies dominated the segment”

Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs and others. Pharmaceutical & biotechnology companies dominated the segment in 2024. With the continuous expansion of R&D pipelines, increased investments in innovative therapies, and the globalization of clinical trials, pharmaceutical and biotechnology companies remain the largest consumers of clinical trial supplies, reinforcing their dominance in the market. Additionally, CROs and CDMOs are expanding their capabilities by integrating digital technologies such as AI-driven supply chain optimization, blockchain for traceability, and real-time inventory management to enhance efficiency and compliance.

“North America: the largest share of the Clinical Trial Supplies market”

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the Clinical Trial Supplies market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of leading academic & research institutions, and significant investment in biotechnology.  The growing adoption of decentralized trials, advanced cold chain logistics, and direct-to-patient (DTP) delivery models has further strengthened the U.S. market. Moreover, the presence of a well-established clinical trial infrastructure, advanced healthcare system, and strong government funding for drug development has contributed to the country’s leading position.  The increasing demand for biologics, biosimilars, and advanced therapies is driving the need for specialized supply chain services, cold chain logistics, and regulatory-compliant distribution networks. With continuous improvements in healthcare infrastructure, favorable government policies, and growing outsourcing trends, APAC is expected to experience robust growth in the clinical trial supplies market in the coming years.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the Clinical Trial Supplies market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

The prominent players operating in the Clinical Trial Supplies market are Almac Group (UK), Novo Holdings A/S (Denmark), Marken (UPS) (US), PCI Pharma Services (US), Sharp Services LLC (US), Thermo Fisher Scientific Inc. (US), Cencora, Inc. (US), Myonex (US), Clinigen Limited (UK), Inceptua Group (Luxembourg), Eurofins Scientific (Luxembourg), Paraxel International Corporation (US), ICON Plc (Ireland), IQVIA (US), Nuvissan GmbH (Germany), Aenova Holding GmbH (Germany), Klifo (Denmark), IPS Pharma (UK), Corex Logistic Limited (Ireland), Biocair (US), Piramal Group (India), Lonza (Switzerland), OCT Group LLC (Germany), Ancillare LP (US), N-SIDE (Belgium), Adallen Pharma (UK), Uniphar Group (Ireland), Clinical Services International (UK) and among others.

Research Coverage:

Clinical Trial Supplies market report is segmented based on services (Logistics & Distribution, Storage & Retention, Packaging, Labeling and Blinding{Primary Packaging, Secondary Packaging and Labeling & Binding}, Manufacturing, Comparator Sourcing , and Other Services), Phase ( Phase I, Phase II, Phase III, Phase IV and Phase BA/BE), Type (Small Molecules, Biologics [Monoclonal Antibodies, Vaccines and Others], Medical Devices), Therapeutic Area (Oncology, Neurology, Respiratory Disorder, Metabolic Disorder/Endocrinology, Cardiovascular System Disorders, Dermatology, Gastrointestinal, Immunological Disorder, Infectious Diseases, Psychiatry, Ophthalmology, Haematology, Genitourinary and Women’s Health, and Others), End Users (pharmaceutical & biotechnology companies, CROs & CDMOs and others). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Clinical Trial Supplies market. A detailed analysis of the key industry players has been done to provide insights into their business overview, services, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the Clinical Trial Supplies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the Clinical Trial Supplies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers ( Increasing Number of Clinical Trials, Technological Advancements in Supply Chain Management), restraints (High Cost of clinical trial supplies), opportunities (Rise of Decentralized & Direct-to-Patient (DTP) Trials) and Challenges ( managing global supply chains) influencing the growth of the market.
• Service Development/Innovation: Detailed insights on upcoming technologies in Clinical Trial Supplies, research and development activities, and new service launches in the Clinical Trial Supplies market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the Clinical Trial Supplies market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players lmac Group (UK), Novo Holdings A/S (Denmark), Marken (UPS) (US), PCI Pharma Services (US), Sharp Services LLC (US), Thermo Fisher Scientific Inc. (US), Cencora, Inc. (US), Myonex (US), Clinigen Limited (UK), Inceptua Group (Luxembourg), Eurofins Scientific (Luxembourg), Paraxel International Corporation (US), ICON Plc (Ireland), IQVIA (US), Nuvissan GmbH (Germany) and among others

Table of Contents

1              INTRODUCTION       38

1.1           STUDY OBJECTIVES 38

1.2           MARKET DEFINITION               38

1.3           MARKET SCOPE       39

1.3.1        MARKETS & REGIONS COVERED             39

1.3.2        INCLUSIONS & EXCLUSIONS   40

1.3.3        YEARS CONSIDERED               40

1.3.4        CURRENCY CONSIDERED        41

1.4           STAKEHOLDERS      41

1.5           SUMMARY OF CHANGES         41

2              RESEARCH METHODOLOGY    43

2.1           RESEARCH DATA     43

2.1.1        SECONDARY DATA  44

2.1.2        PRIMARY RESEARCH               45

2.2           MARKET SIZE ESTIMATION     46

2.2.1        GLOBAL MARKET ESTIMATION                46

2.2.1.1    Insights from primary experts 48

2.2.2        SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 49

2.3           MARKET GROWTH RATE PROJECTIONS  50

2.4           DATA TRIANGULATION             52

2.5           RESEARCH ASSUMPTIONS      53

2.6           RESEARCH LIMITATIONS         54

2.7           RISK ANALYSIS        54

3              EXECUTIVE SUMMARY             55

4              PREMIUM INSIGHTS                60

4.1           CLINICAL TRIAL SUPPLIES MARKET OVERVIEW      60

4.2           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE AND COUNTRY (2024)    61

4.3           CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE, 2025 VS. 2030                 61

4.4           CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES      62

5              MARKET OVERVIEW 63

5.1           INTRODUCTION       63

5.2           MARKET DYNAMICS                 64

5.2.1        DRIVERS  65

5.2.1.1    Growth in clinical trials & drug development           65

5.2.1.2    Expansion of global and multicenter trials accelerating demand for clinical trial supplies                66

5.2.1.3    Rising demand for personalized medicine and biologics        66

5.2.2        RESTRAINTS            67

5.2.2.1    High costs associated with clinical trial supplies    67

5.2.3        OPPORTUNITIES      67

5.2.3.1    Rise in decentralized and virtual trials   67

5.2.3.2    Integration of digital technologies in supply chain management                 68

5.2.4        CHALLENGES           68

5.2.4.1    Supply chain disruptions and drug shortages         68

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES                 69

5.4           VALUE CHAIN ANALYSIS          69

5.5           ECOSYSTEM ANALYSIS            72

5.5.1        CLINICAL TRIAL SUPPLIES MARKET: RAW MATERIAL PROVIDERS                 73

5.5.2        CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS    73

5.5.3        CLINICAL TRIAL SUPPLIES MARKET: END USERS   74

5.5.4        CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES   74

5.6           PRICING ANALYSIS  75

5.6.1        AVERAGE SELLING PRICE, BY KEY PLAYER (QUALITATIVE)     75

5.6.2        INDICATIVE PRICE, BY SERVICE (QUALITATIVE)       76

5.7           INVESTMENT AND FUNDING SCENARIO 77

5.8           TECHNOLOGY ANALYSIS          77

5.8.1        KEY TECHNOLOGIES                77

5.8.1.1    Serialization & track-and-trace technologies           77

5.8.1.2    Interactive response technology (IRT/IVR/IWR)      78

5.8.1.3    Cold chain & temperature monitoring solutions     78

5.8.2        COMPLEMENTARY TECHNOLOGIES        78

5.8.2.1    Artificial intelligence (AI) & machine learning (ML) 78

5.8.2.2    Blockchain for supply chain transparency               78

5.8.3        ADJACENT TECHNOLOGIES     78

5.8.3.1    Cryopreservation & advanced storage technologies               78

5.8.3.2    Advanced robotics in warehousing & distribution  79

5.9           KEY CONFERENCES AND EVENTS, 2025–2026    79

5.10         REGULATORY LANDSCAPE      80

5.10.1     REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS      80

5.10.2     REGULATORY FRAMEWORK    83

5.10.2.1  North America         83

5.10.2.1.1               US            83

5.10.2.1.2               Canada   84

5.10.2.2  Europe     84

5.10.2.2.1               Germany  84

5.10.2.2.2               France     84

5.10.2.2.3               Italy          84

5.10.2.3  Asia Pacific              84

5.10.2.3.1               Japan      84

5.10.2.3.2               China       84

5.10.2.3.3               India        84

5.10.2.4  Latin America          85

5.10.2.4.1               Brazil       85

5.10.2.5  Middle East & Africa                85

5.10.2.5.1               GCC Countries         85

5.10.2.5.2               South Africa             85

5.11         PORTER’S FIVE FORCES ANALYSIS          85

5.11.1     THREAT OF NEW ENTRANTS   86

5.11.2     BARGAINING POWER OF SUPPLIERS       86

5.11.3     BARGAINING POWER OF BUYERS            87

5.11.4     THREAT OF SUBSTITUTES        87

5.11.5     INTENSITY OF COMPETITIVE RIVALRY     87

5.12         KEY STAKEHOLDERS AND BUYING CRITERIA          87

5.12.1     KEY STAKEHOLDERS IN BUYING PROCESS             88

5.12.2     BUYING CRITERIA    89

5.13         IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL SUPPLIES MARKET                 90

5.13.1     INTRODUCTION       90

5.13.2     FUTURE OF GENERATIVE AI IN CLINICAL TRIAL SUPPLIES ECOSYSTEM                 92

6              CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE   93

6.1           INTRODUCTION       94

6.2           LOGISTICS & DISTRIBUTION SERVICES   94

6.2.1        RISING DEMAND DUE TO INCREASING EMPHASIS ON CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH      94

6.3           COMPARATOR SOURCING SERVICES      98

6.3.1        RISING DEMAND FOR COMPARATOR SOURCING TO DRIVE MARKET                 98

6.4           PACKAGING, LABELING, AND BLINDING SERVICES                 101

6.4.1        PRIMARY PACKAGING SERVICES             105

6.4.1.1    Increasing demand for innovative drug formulations to support market growth     105

6.4.2        SECONDARY PACKAGING SERVICES       108

6.4.2.1    Increasing complexity of global clinical trials to propel market                 108

6.4.3        LABELING & BLINDING SERVICES           111

6.4.3.1    Rising number of randomized and double-blind studies to propel market     111

6.5           MANUFACTURING SERVICES   114

6.5.1        RISING DEMAND FOR ULTRA-LOW-TEMPERATURE STORAGE TO DRIVE GROWTH 114

6.6           STORAGE & RETENTION SERVICES         117

6.6.1        RISING DEMAND FOR ULTRA-LOW-TEMPERATURE STORAGE TO DRIVE GROWTH 117

6.7           OTHER SERVICES    121

7              CLINICAL TRIAL SUPPLIES MARKET, BY PHASE      125

7.1           INTRODUCTION       126

7.2           PHASE III 126

7.2.1        DEVELOPMENT OF BIOLOGICS AND ADVANCED THERAPIES TO SUPPORT MARKET GROWTH  126

7.3           PHASE II  130

7.3.1        NEED FOR GREATER EFFICIENCY AND COMPLIANCE IN TRIAL LOGISTICS TO SUPPORT MARKET GROWTH            130

7.4           PHASE I   133

7.4.1        RISING COMPLEXITY OF INVESTIGATIONAL DRUGS TO DRIVE MARKET GROWTH 133

7.5           PHASE IV 137

7.5.1        INCREASING FOCUS ON PATIENT-CENTRIC APPROACHES TO DRIVE MARKET GROWTH   137

7.6           PHASE BA/BE          140

7.6.1        ACCELERATING GENERIC DRUG APPROVALS THROUGH OPTIMIZED BA/BE STUDIES TO SUPPORT MARKET GROWTH   140

8              CLINICAL TRIAL SUPPLIES MARKET, BY TYPE         144

8.1           INTRODUCTION       145

8.2           SMALL MOLECULES                 145

8.2.1        HIGH VOLUME OF SMALL-MOLECULE CLINICAL TRIALS          145

8.3           BIOLOGICS               149

8.3.1        MONOCLONAL ANTIBODIES    153

8.3.1.1    Rising demand for monoclonal antibodies to drive growth     153

8.3.2        VACCINES                156

8.3.2.1    Increased focus on development of novel vaccines to drive growth                 156

8.3.3        OTHER BIOLOGICS  160

8.4           MEDICAL DEVICES  163

8.4.1        RISING DEMAND FOR SPECIALIZED LOGISTICS IN MEDICAL DEVICE CLINICAL TRIALS TO DRIVE MARKET GROWTH       163

9              CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA 167

9.1           INTRODUCTION       168

9.2           ONCOLOGY              169

9.2.1        RISING DISEASE BURDEN TO SUPPORT MARKET GROWTH   169

9.3           NEUROLOGY            173

9.3.1        INCREASING R&D INVESTMENT TO SUPPORT MARKET GROWTH                 173

9.4           RESPIRATORY DISORDERS     177

9.4.1        RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH   177

9.5           METABOLIC DISORDERS/ENDOCRINOLOGY           180

9.5.1        INCREASING GLOBAL DIABETES POPULATION TO SUPPORT MARKET GROWTH 180

9.6           CARDIOVASCULAR SYSTEM DISORDERS                 184

9.6.1        RISING DEMAND IN CLINICAL DIAGNOSTICS TO PROPEL MARKET GROWTH 184

9.7           DERMATOLOGY       187

9.7.1        GROWING FOCUS ON DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH 187

9.8           GASTROINTESTINAL SYSTEM DISORDERS              191

9.8.1        INCREASING INCIDENCE OF LIFESTYLE AND DIETARY RISK FACTORS TO DRIVE DEMAND       191

9.9           IMMUNOLOGICAL DISORDERS                194

9.9.1        GROWING CLINICAL RESEARCH TO SUPPORT MARKET GROWTH                 194

9.10         INFECTIOUS DISEASES            198

9.10.1     RISING OUTBREAKS OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH 198

9.11         PSYCHIATRY             202

9.11.1     RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL MARKET GROWTH 202

9.12         OPHTHALMOLOGY  205

9.12.1     RISING NUMBER OF OPHTHALMIC PIPELINE DRUGS TO AID MARKET GROWTH 205

9.13         HEMATOLOGY          209

9.13.1     INTEGRATION OF ADVANCED SUPPLY CHAIN TECHNOLOGIES TO FUEL MARKET GROWTH   209

9.14         GENITOURINARY & WOMEN’S HEALTH   212

9.14.1     RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET GROWTH   212

9.15         OTHER THERAPEUTIC AREAS  216

10            CLINICAL TRIAL SUPPLIES MARKET, BY REGION    220

10.1         INTRODUCTION       221

10.2         NORTH AMERICA     221

10.2.1     MACROECONOMIC OUTLOOK FOR NORTH AMERICA              222

10.2.2     US            227

10.2.2.1  Robust hospital infrastructure and drug research & development to stimulate growth     227

10.2.3     CANADA   230

10.2.3.1  Growing preference of pharmaceutical companies to conduct trials to favor growth             230

10.3         EUROPE   234

10.3.1     MACROECONOMIC OUTLOOK FOR EUROPE            234

10.3.2     GERMANY                239

10.3.2.1  Growing focus on reducing approval timelines and high spending by global pharmaceutical players to propel market    239

10.3.3     UK            243

10.3.3.1  Expanding tax credits leading to encourage growth                243

10.3.4     FRANCE   246

10.3.4.1  Evolving regulatory landscape to stimulate growth 246

10.3.5     ITALY        250

10.3.5.1  Increasing number of drug approvals to accelerate growth   250

10.3.6     SPAIN       253

10.3.6.1  Favorable clinical trial network in public health system to sustain growth                 253

10.3.7     SWITZERLAND         256

10.3.7.1  Presence of multinational corporations and small and medium-sized pharmaceutical companies to fuel market              256

10.3.8     NETHERLANDS        260

10.3.8.1  Increasing collaborations among pharmaceutical giants to promote growth     260

10.3.9     REST OF EUROPE    263

10.4         ASIA PACIFIC            267

10.4.1     MACROECONOMIC OUTLOOK FOR ASIA PACIFIC    267

10.4.2     CHINA      273

10.4.2.1  High proportion of domestic industry-sponsored trials to speed up growth     273

10.4.3     JAPAN      277

10.4.3.1  Increasing focus on lowering regulatory timelines to facilitate growth                 277

10.4.4     INDIA       280

10.4.4.1  Rise in early-phase clinical trials to spur growth     280

10.4.5     AUSTRALIA               284

10.4.5.1  Increasing research funding to favor growth           284

10.4.6     SOUTH KOREA         287

10.4.6.1  Growing focus on new drug development research to drive market                 287

10.4.7     SINGAPORE              291

10.4.7.1  Advanced research facilities to intensify growth     291

10.4.8     REST OF ASIA PACIFIC             294

10.5         LATIN AMERICA       298

10.5.1     MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 298

10.5.2     BRAZIL     302

10.5.2.1  Regulatory improvements to support growth          302

10.5.3     MEXICO   306

10.5.3.1  Expanding landscape of clinical trials to boost market           306

10.5.4     REST OF LATIN AMERICA         309

10.6         MIDDLE EAST          312

10.6.1     MACROECONOMIC OUTLOOK FOR MIDDLE EAST   312

10.6.2     GCC COUNTRIES      317

10.6.2.1  Saudi Arabia            320

10.6.2.1.1               Booming investments in research infrastructure and life sciences development to aid growth       320

10.6.2.2  UAE          324

10.6.2.2.1               Increasing public-private partnerships and genomic research initiatives to augment growth  324

10.6.2.3  Rest of GCC Countries             327

10.6.3     REST OF MIDDLE EAST            330

10.7         AFRICA     333

10.7.1     GROWING DEMAND FOR OUTSOURCING SERVICES TO DRIVE MARKET GROWTH 333

10.7.2     MACROECONOMIC OUTLOOK FOR AFRICA              334

11            COMPETITIVE LANDSCAPE      338

11.1         INTRODUCTION       338

11.2         KEY PLAYER STRATEGIES/RIGHT TO WIN                338

11.2.1     OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET        338

11.3         REVENUE ANALYSIS, 2020–2024          340

11.4         MARKET SHARE ANALYSIS, 2024           341

11.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024           343

11.5.1     STARS      343

11.5.2     EMERGING LEADERS               343

11.5.3     PERVASIVE PLAYERS               343

11.5.4     PARTICIPANTS         343

11.5.5     COMPANY FOOTPRINT: KEY PLAYERS, 2024          345

11.5.5.1  Company footprint  345

11.5.5.2  Region footprint       346

11.5.5.3  Service footprint      347

11.5.5.4  Type footprint          348

11.5.5.5  End-user footprint   349

11.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024     349

11.6.1     PROGRESSIVE COMPANIES    349

11.6.2     RESPONSIVE COMPANIES       349

11.6.3     DYNAMIC COMPANIES             350

11.6.4     STARTING BLOCKS 350

11.6.5     COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024     351

11.6.5.1  Detailed list of key startups/SMEs          351

11.6.5.2  Competitive benchmarking of key startups/SMEs  352

11.7         COMPANY VALUATION & FINANCIAL METRICS        353

11.7.1     COMPANY VALUATION             353

11.7.2     FINANCIAL METRICS                353

11.8         BRAND/SERVICE COMPARISON              354

11.9         COMPETITIVE SCENARIO         355

11.9.1     DEALS      355

11.9.2     EXPANSIONS            356

12            COMPANY PROFILES                357

12.1         KEY PLAYERS           357

12.1.1     THERMO FISHER SCIENTIFIC INC.           357

12.1.1.1  Business overview   357

12.1.1.2  Services offered      358

12.1.1.3  Recent developments              359

12.1.1.3.1               Service launches     359

12.1.1.3.2               Deals       359

12.1.1.3.3               Expansions              360

12.1.1.4  MnM view                 360

12.1.1.4.1               Right to win              360

12.1.1.4.2               Strategic choices     360

12.1.1.4.3               Weaknesses & competitive threats         360

12.1.2     NOVO HOLDINGS A/S              361

12.1.2.1  Business overview   361

12.1.2.2  Services offered      362

12.1.2.3  Recent developments              363

12.1.2.3.1               Deals       363

12.1.2.3.2               Expansions              364

12.1.2.4  MnM view                 364

12.1.2.4.1               Right to win              364

12.1.2.4.2               Strategic choices     364

12.1.2.4.3               Weaknesses & competitive threats         365

12.1.3     UNITED PARCEL SERVICE OF AMERICA, INC.          366

12.1.3.1  Business overview   366

12.1.3.2  Services offered      366

12.1.3.3  MnM view                 367

12.1.3.3.1               Right to win              367

12.1.3.3.2               Strategic choices     367

12.1.3.3.3               Weaknesses & competitive threats         368

12.1.4     EUROFINS SCIENTIFIC             369

12.1.4.1  Business overview   369

12.1.4.2  Services offered      370

12.1.4.3  MnM view                 371

12.1.4.3.1               Right to win              371

12.1.4.3.2               Strategic choices     371

12.1.4.3.3               Weaknesses & competitive threats         371

12.1.5     PIRAMAL PHARMA LIMITED    372

12.1.5.1  Business overview   372

12.1.5.2  Services offered      373

12.1.5.3  MnM view                 374

12.1.5.3.1               Right to win              374

12.1.5.3.2               Strategic choices     374

12.1.5.3.3               Weaknesses & competitive threats         374

12.1.6     IQVIA        375

12.1.6.1  Business overview   375

12.1.6.2  Services offered      377

12.1.7     ICON PLC 378

12.1.7.1  Business overview   378

12.1.7.2  Services offered      379

12.1.7.3  Recent developments              380

12.1.7.3.1               Deals       380

12.1.8     LONZA     381

12.1.8.1  Business overview   381

12.1.8.2  Services offered      382

12.1.8.3  Recent developments              382

12.1.8.3.1               Deals       382

12.1.9     UNIPHAR GROUP PLC              383

12.1.9.1  Business overview   383

12.1.9.2  Services offered      384

12.1.10   ALMAC GROUP         385

12.1.10.1                Business overview   385

12.1.10.2                Services offered      385

12.1.10.3                Recent developments              386

12.1.10.3.1             Expansions              386

12.1.11   SHARP SERVICES, LLC            387

12.1.11.1                Business overview   387

12.1.11.2                Services offered      387

12.1.12   PCI PHARMA SERVICES           389

12.1.12.1                Business overview   389

12.1.12.2                Services offered      389

12.1.12.3                Recent developments              390

12.1.12.3.1             Expansions              390

12.1.13   PAREXEL INTERNATIONAL (MA) CORPORATION      391

12.1.13.1                Business overview   391

12.1.13.2                Services offered      391

12.1.13.3                Recent developments              392

12.1.13.3.1             Deals       392

12.1.14   BIOCAIR   393

12.1.14.1                Business overview   393

12.1.14.2                Services offered      393

12.2         OTHER PLAYERS      394

12.2.1     CENCORA, INC.        394

12.2.2     CLINIGEN LIMITED  395

12.2.3     KLIFO       396

12.2.4     IPS PHARMA            397

12.2.5     COREX LOGISTICS LIMITED     398

12.2.6     OCT GROUP LLC      399

12.2.7     MYONEX  400

12.2.8     INCEPTUA GROUP    401

12.2.9     ANCILLARE, LP         402

12.2.10   ADALLEN PHARMA  403

12.2.11   CLINICAL SERVICES INTERNATIONAL (CSI)              404

12.2.12   NUVISAN GMBH       405

12.2.13   AENOVA HOLDING GMBH        406

13            APPENDIX                 407

13.1         DISCUSSION GUIDE 407

13.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                 411

13.3         CUSTOMIZATION OPTIONS      413

13.4         RELATED REPORTS 413

13.5         AUTHOR DETAILS    414

LIST OF TABLES

TABLE 1   IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS                 51

TABLE 2   CLINICAL TRIAL SUPPLIES MARKET: RISK ASSESSMENT ANALYSIS                 54

TABLE 3   CLINICAL TRIAL SUPPLIES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS               64

TABLE 4   CLINICAL TRIAL SUPPLIES MARKET: PRODUCT MANUFACTURERS                 73

TABLE 5   CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS    73

TABLE 6   CLINICAL TRIAL SUPPLIES MARKET: END USERS   74

TABLE 7   CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES   74

TABLE 8   CLINICAL TRIAL SUPPLIES MARKET: KEY CONFERENCES AND EVENTS,

2025–2026            79

TABLE 9   NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80

TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS      81

TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          82

TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          83

TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                83

TABLE 14 CLINICAL TRIAL SUPPLIES MARKET: PORTER’S FIVE FORCES ANALYSIS                 85

TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER                 88

TABLE 16 KEY BUYING CRITERIA FOR CLINICAL TRIAL SUPPLIES PRODUCTS, BY END USER                89

TABLE 17 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION) 94

TABLE 18 CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES,

BY REGION, 2023–2030 (USD MILLION)                95

TABLE 19 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)   95

TABLE 20 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)   96

TABLE 21 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)   96

TABLE 22 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)   97

TABLE 23 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY REGION, 2023–2030 (USD MILLION)      97

TABLE 24 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)   97

TABLE 25 CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES,

BY REGION, 2023–2030 (USD MILLION)                98

TABLE 26 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 99

TABLE 27 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)         99

TABLE 28 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)         100

TABLE 29 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)         100

TABLE 30 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2023–2030 (USD MILLION)            100

TABLE 31 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 101

TABLE 32 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 102

TABLE 33 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2023–2030 (USD MILLION)             102

TABLE 34 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 102

TABLE 35 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 103

TABLE 36 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 103

TABLE 37 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 104

TABLE 38 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2023–2030 (USD MILLION)                 104

TABLE 39 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 104

TABLE 40 PRIMARY PACKAGING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)         105

TABLE 41 NORTH AMERICA: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   105

TABLE 42 EUROPE: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   106

TABLE 43 ASIA PACIFIC: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   106

TABLE 44 LATIN AMERICA: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   107

TABLE 45 MIDDLE EAST: PRIMARY PACKAGING SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)   107

TABLE 46 GCC COUNTRIES: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   107

TABLE 47 SECONDARY PACKAGING SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)   108

TABLE 48 NORTH AMERICA: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)  108

TABLE 49 EUROPE: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   109

TABLE 50 ASIA PACIFIC: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   109

TABLE 51 LATIN AMERICA: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)  110

TABLE 52 MIDDLE EAST: SECONDARY PACKAGING SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)   110

TABLE 53 GCC COUNTRIES: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)  110

TABLE 54 LABELING & BLINDING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)         111

TABLE 55 NORTH AMERICA: LABELING & BLINDING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   111

TABLE 56 EUROPE: LABELING & BLINDING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   112

TABLE 57 ASIA PACIFIC: LABELING & BLINDING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   112

TABLE 58 LATIN AMERICA: LABELING & BLINDING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   113

TABLE 59 MIDDLE EAST: LABELING & BLINDING SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)   113

TABLE 60 GCC COUNTRIES: LABELING & BLINDING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   113

TABLE 61 CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD MILLION)                114

TABLE 62 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 115

TABLE 63 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)             115

TABLE 64 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 116

TABLE 65 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 116

TABLE 66 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD MILLION)                 116

TABLE 67 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 117

TABLE 68 CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES,

BY REGION, 2023–2030 (USD MILLION)                118

TABLE 69 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)       118

TABLE 70 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)       119

TABLE 71 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)       119

TABLE 72 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)       120

TABLE 73 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY REGION, 2023–2030 (USD MILLION)          120

TABLE 74 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)       120

TABLE 75 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY REGION,

2023–2030 (USD MILLION)   121

TABLE 76 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)             122

TABLE 77 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)  122

TABLE 78 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)             123

TABLE 79 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)             123

TABLE 80 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES,

BY REGION, 2023–2030 (USD MILLION)                123

TABLE 81 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)           124

TABLE 82 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION) 126

TABLE 83 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS, BY REGION,

2023–2030 (USD MILLION)   127

TABLE 84 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             127

TABLE 85 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS, BY COUNTRY, 2023–2030 (USD MILLION)  128

TABLE 86 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             128

TABLE 87 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             129

TABLE 88 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS,

BY REGION, 2023–2030 (USD MILLION)                129

TABLE 89 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             129

TABLE 90 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS, BY REGION,

2023–2030 (USD MILLION)   130

TABLE 91 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             131

TABLE 92 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS, BY COUNTRY, 2023–2030 (USD MILLION)  131

TABLE 93 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             132

TABLE 94 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             132

TABLE 95 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS,

BY REGION, 2023–2030 (USD MILLION)                132

TABLE 96 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             133

TABLE 97 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS, BY REGION,

2023–2030 (USD MILLION)   134

TABLE 98 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             134

TABLE 99 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS, BY COUNTRY, 2023–2030 (USD MILLION)  135

TABLE 100               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             135

TABLE 101               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             136

TABLE 102               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS,

BY REGION, 2023–2030 (USD MILLION)                136

TABLE 103               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             136

TABLE 104               CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS, BY REGION,

2023–2030 (USD MILLION)   137

TABLE 105               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             138

TABLE 106               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS, BY COUNTRY, 2023–2030 (USD MILLION)                138

TABLE 107               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             139

TABLE 108               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             139

TABLE 109               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS,

BY REGION, 2023–2030 (USD MILLION)                139

TABLE 110               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS,

BY COUNTRY, 2023–2030 (USD MILLION)             140

TABLE 111               CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY REGION, 2023–2030 (USD MILLION)                141

TABLE 112               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)      141

TABLE 113               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES,

BY COUNTRY, 2023–2030 (USD MILLION)             142

TABLE 114               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES,

BY COUNTRY, 2023–2030 (USD MILLION)             142

TABLE 115               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)      143

TABLE 116               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES,

BY REGION, 2023–2030 (USD MILLION)                143

TABLE 117               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)      143

TABLE 118               CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)         145

TABLE 119               CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES, BY REGION,

2023–2030 (USD MILLION)   146

TABLE 120               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES,

BY COUNTRY, 2023–2030 (USD MILLION)             146

TABLE 121               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES,

BY COUNTRY, 2023–2030 (USD MILLION)             147

TABLE 122               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES,

BY COUNTRY, 2023–2030 (USD MILLION)             147

TABLE 123               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES,

BY COUNTRY, 2023–2030 (USD MILLION)             148

TABLE 124               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES,

BY REGION, 2023–2030 (USD MILLION)                148

TABLE 125               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES,

BY COUNTRY, 2023–2030 (USD MILLION)             148

TABLE 126               CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   149

TABLE 127               CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY REGION,

2023–2030 (USD MILLION)   150

TABLE 128               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS,

BY COUNTRY, 2023–2030 (USD MILLION)             150

TABLE 129              EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY COUNTRY,

2023–2030 (USD MILLION)   151

TABLE 130               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)         151

TABLE 131               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)         152

TABLE 132               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION)            152

TABLE 133               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS,

BY COUNTRY, 2023–2030 (USD MILLION)             152

TABLE 134               CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)          153

TABLE 135               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)                 154

TABLE 136               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES,

BY COUNTRY, 2023–2030 (USD MILLION)             154

TABLE 137               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)                 155

TABLE 138               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)                 155

TABLE 139               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)  155

TABLE 140               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)                 156

TABLE 141               CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY REGION,

2023–2030 (USD MILLION)   157

TABLE 142               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES,

BY COUNTRY, 2023–2030 (USD MILLION)             157

TABLE 143               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY,

2023–2030 (USD MILLION)   158

TABLE 144               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION)           158

TABLE 145               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION)           159

TABLE 146               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY REGION, 2023–2030 (USD MILLION)              159

TABLE 147               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION)           159

TABLE 148               CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS, BY REGION,

2023–2030 (USD MILLION)   160

TABLE 149               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS,

BY COUNTRY, 2023–2030 (USD MILLION)             161

TABLE 150               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)         161

TABLE 151               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS,

BY COUNTRY, 2023–2030 (USD MILLION)             162

TABLE 152               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS,

BY COUNTRY, 2023–2030 (USD MILLION)             162

TABLE 153               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS,

BY REGION, 2023–2030 (USD MILLION)                162

TABLE 154               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS,

BY COUNTRY, 2023–2030 (USD MILLION)             163

TABLE 155               CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY REGION,

2023–2030 (USD MILLION)   164

TABLE 156               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES,

BY COUNTRY, 2023–2030 (USD MILLION)             164

TABLE 157               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2023–2030 (USD MILLION)             165

TABLE 158               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES,

BY COUNTRY, 2023–2030 (USD MILLION)             165

TABLE 159               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES,

BY COUNTRY, 2023–2030 (USD MILLION)             166

TABLE 160               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES,

BY REGION, 2023–2030 (USD MILLION)                166

TABLE 161               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES,

BY COUNTRY, 2023–2030 (USD MILLION)             166

TABLE 162               CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   168

TABLE 163               US: NUMBER OF NEW CANCER CASES, BY TYPE, 2022 VS. 2040       169

TABLE 164               CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION,

2023–2030 (USD MILLION)   170

TABLE 165               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             170

TABLE 166              EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)             171

TABLE 167               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)         171

TABLE 168               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)         172

TABLE 169               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)            172

TABLE 170               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             172

TABLE 171               CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY REGION,

2023–2030 (USD MILLION)   174

TABLE 172               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             174

TABLE 173               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)       175

TABLE 174               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)       175

TABLE 175               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             176

TABLE 176               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION)          176

TABLE 177               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)       176

TABLE 178               CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION)          177

TABLE 179               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)                 178

TABLE 180               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)             178

TABLE 181               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)                 179

TABLE 182               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)                 179

TABLE 183               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION)   179

TABLE 184               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)                 180

TABLE 185               CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2023–2030 (USD MILLION)                 181

TABLE 186               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 181

TABLE 187               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 182

TABLE 188               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 182

TABLE 189               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 183

TABLE 190               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2023–2030 (USD MILLION) 183

TABLE 191               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 183

TABLE 192               CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION)            184

TABLE 193               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 185

TABLE 194               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 185

TABLE 195               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 186

TABLE 196               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 186

TABLE 197               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION)                 186

TABLE 198               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 187

TABLE 199               CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY, BY REGION,

2023–2030 (USD MILLION)   188

TABLE 200               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             188

TABLE 201               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)  189

TABLE 202               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             189

TABLE 203               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             190

TABLE 204               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY,

BY REGION, 2023–2030 (USD MILLION)                190

TABLE 205               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             190

TABLE 206               CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION)            191

TABLE 207               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 192

TABLE 208               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 192

TABLE 209               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193

TABLE 210               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 193

TABLE 211               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION) 194

TABLE 212               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 194

TABLE 213               CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)          195

TABLE 214               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)                 195

TABLE 215               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)                 196

TABLE 216               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)                 196

TABLE 217               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)                 197

TABLE 218               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)                 197

TABLE 219               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)                 197

TABLE 220               CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)              199

TABLE 221               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)      199

TABLE 222               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)             200

TABLE 223               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)             200

TABLE 224               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)      201

TABLE 225               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES,

BY REGION, 2023–2030 (USD MILLION)                201

TABLE 226               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)      201

TABLE 227               CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY REGION,

2023–2030 (USD MILLION)   202

TABLE 228               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY,

BY COUNTRY, 2023–2030 (USD MILLION)             203

TABLE 229               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION)       203

TABLE 230               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2030 (USD MILLION)       204

TABLE 231               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY,

BY COUNTRY, 2023–2030 (USD MILLION)             204

TABLE 232               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY REGION, 2023–2030 (USD MILLION)          204

TABLE 233               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY,

BY COUNTRY, 2023–2030 (USD MILLION)             205

TABLE 234               CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY, BY REGION,

2023–2030 (USD MILLION)   206

TABLE 235               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             206

TABLE 236               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)              207

TABLE 237               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             207

TABLE 238               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             208

TABLE 239               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY,

BY REGION, 2023–2030 (USD MILLION)                208

TABLE 240               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             208

TABLE 241               CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY REGION,

2023–2030 (USD MILLION)   209

TABLE 242               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             210

TABLE 243               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)    210

TABLE 244               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)    211

TABLE 245               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             211

TABLE 246               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY REGION, 2023–2030 (USD MILLION)       211

TABLE 247               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)             212

TABLE 248               CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,

BY REGION, 2023–2030 (USD MILLION)              213

TABLE 249               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)                 213

TABLE 250               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)                 214

TABLE 251               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)                 214

TABLE 252               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)                 215

TABLE 253               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION)                 215

TABLE 254               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)                 215

TABLE 255               CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)            216

TABLE 256               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)                 217

TABLE 257               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)         217

TABLE 258               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)         218

TABLE 259               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)                 218

TABLE 260               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)                 218

TABLE 261               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)                 219

TABLE 262               CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2023–2030 (USD MILLION)         221

TABLE 263               NORTH AMERICA: KEY MACROECONOMIC INDICATORS                 222

TABLE 264               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   223

TABLE 265               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   224

TABLE 266               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 224

TABLE 267               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   225

TABLE 268               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   225

TABLE 269               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 225

TABLE 270               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)  226

TABLE 271               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   226

TABLE 272               US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION)               227

TABLE 273               US: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 228

TABLE 274               US: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION)               228

TABLE 275               US: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)               228

TABLE 276               US: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   229

TABLE 277               US: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   229

TABLE 278               US: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION)   230

TABLE 279               CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   231

TABLE 280               CANADA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 231

TABLE 281               CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   232

TABLE 282               CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)   232

TABLE 283               CANADA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   232

TABLE 284               CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   233

TABLE 285               CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   233

TABLE 286               EUROPE: KEY MACROECONOMIC INDICATORS       235

TABLE 287               EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   235

TABLE 288               EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   236

TABLE 289               EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 236

TABLE 290               EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   237

TABLE 291               EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)   237

TABLE 292               EUROPE: CLINICAL TRIAL SUPPLIES MARKE FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   237

TABLE 293               EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   238

TABLE 294               EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   238

TABLE 295               GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   240

TABLE 296               GERMANY: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 240

TABLE 297               GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   241

TABLE 298               GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   241

TABLE 299               GERMANY: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   241

TABLE 300               GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   242

TABLE 301              GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   242

TABLE 302               UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION)               243

TABLE 303               UK: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 244

TABLE 304               UK: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION)               244

TABLE 305               UK: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)               244

TABLE 306               UK: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   245

TABLE 307               UK: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   245

TABLE 308               UK: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION)   246

TABLE 309               FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   247

TABLE 310               FRANCE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 247

TABLE 311               FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   248

TABLE 312               FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)   248

TABLE 313               FRANCE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   248

TABLE 314               FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION) 249

TABLE 315               FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   249

TABLE 316               ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   250

TABLE 317               ITALY: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 251

TABLE 318               ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION)               251

TABLE 319               ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)               251

TABLE 320               ITALY: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   252

TABLE 321               ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   252

TABLE 322               ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   253

TABLE 323               SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   253

TABLE 324               SPAIN: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 254

TABLE 325               SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION)               254

TABLE 326               SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)               254

TABLE 327               SPAIN: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   255

TABLE 328               SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   255

TABLE 329               SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   256

TABLE 330               SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   257

TABLE 331               SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 257

TABLE 332               SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   258

TABLE 333               SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   258

TABLE 334               SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 258

TABLE 335               SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   259

TABLE 336               SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   259

TABLE 337               NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   260

TABLE 338               NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 261

TABLE 339               NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   261

TABLE 340               NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   261

TABLE 341               NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 262

TABLE 342               NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)  262

TABLE 343               NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   263

TABLE 344               REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   264

TABLE 345               REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 264

TABLE 346               REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   265

TABLE 347               REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   265

TABLE 348               REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 265

TABLE 349               REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)  266

TABLE 350               REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   266

TABLE 351               ASIA PACIFIC: KEY MACROECONOMIC INDICATORS                 268

TABLE 352               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   270

TABLE 353               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   270

TABLE 354               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 271

TABLE 355               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   271

TABLE 356               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   271

TABLE 357               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   272

TABLE 358               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   272

TABLE 359               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   273

TABLE 360               CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   274

TABLE 361               CHINA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 274

TABLE 362               CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION)   275

TABLE 363               CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)               275

TABLE 364               CHINA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   275

TABLE 365               CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   276

TABLE 366               CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   276

TABLE 367               JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   277

TABLE 368               JAPAN: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 278

TABLE 369               JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION)   278

TABLE 370               JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)               278

TABLE 371               JAPAN: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   279

TABLE 372               JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   279

TABLE 373               JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   280

TABLE 374               INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   281

TABLE 375               INDIA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 281

TABLE 376               INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION)               282

TABLE 377               INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)               282

TABLE 378               INDIA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   282

TABLE 379               INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   283

TABLE 380               INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   283

TABLE 381               AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   284

TABLE 382               AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 285

TABLE 383               AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   285

TABLE 384               AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   285

TABLE 385               AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   286

TABLE 386               AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   286

TABLE 387               AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   287

TABLE 388               SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   288

TABLE 389               SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 288

TABLE 390               SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   289

TABLE 391               SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   289

TABLE 392               SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 289

TABLE 393               SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   290

TABLE 394               SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   290

TABLE 395              SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   291

TABLE 396               SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 292

TABLE 397               SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   292

TABLE 398               SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   292

TABLE 399               SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   293

TABLE 400               SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   293

TABLE 401               SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   294

TABLE 402               REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   295

TABLE 403               REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)         295

TABLE 404               REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   296

TABLE 405               REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   296

TABLE 406               REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS,

BY TYPE, 2023–2030 (USD MILLION)    296

TABLE 407               REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)             297

TABLE 408               REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   297

TABLE 409               LATIN AMERICA: KEY MACROECONOMIC INDICATORS                 299

TABLE 410               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   299

TABLE 411               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   299

TABLE 412               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 300

TABLE 413               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   300

TABLE 414              LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   300

TABLE 415               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 301

TABLE 416               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)  301

TABLE 417               LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   302

TABLE 418               BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   303

TABLE 419               BRAZIL: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 303

TABLE 420               BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   304

TABLE 421               BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)               304

TABLE 422               BRAZIL: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   304

TABLE 423               BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   305

TABLE 424               BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   305

TABLE 425               MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   306

TABLE 426              MEXICO: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 307

TABLE 427               MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   307

TABLE 428               MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)   307

TABLE 429               MEXICO: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   308

TABLE 430               MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   308

TABLE 431               MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   309

TABLE 432               REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   309

TABLE 433               REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)         310

TABLE 434               REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   310

TABLE 435               REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   310

TABLE 436               REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS,

BY TYPE, 2023–2030 (USD MILLION)    311

TABLE 437               REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)             311

TABLE 438               REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION)            312

TABLE 439               MIDDLE EAST: KEY MACROECONOMIC INDICATORS                 313

TABLE 440               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY REGION,

2023–2030 (USD MILLION)   313

TABLE 441               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   314

TABLE 442               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 314

TABLE 443              MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   315

TABLE 444               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   315

TABLE 445               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 315

TABLE 446               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   316

TABLE 447               MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   316

TABLE 448               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)   317

TABLE 449               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   317

TABLE 450               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 318

TABLE 451               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   318

TABLE 452               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   318

TABLE 453               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 319

TABLE 454               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)  319

TABLE 455               GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   320

TABLE 456               SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   321

TABLE 457               SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION) 321

TABLE 458              SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   322

TABLE 459               SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   322

TABLE 460               SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION) 322

TABLE 461               SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   323

TABLE 462               SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   323

TABLE 463               UAE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2030 (USD MILLION)               324

TABLE 464               UAE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 325

TABLE 465               UAE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2030 (USD MILLION)               325

TABLE 466               UAE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)               325

TABLE 467               UAE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   326

TABLE 468               UAE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   326

TABLE 469               UAE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   327

TABLE 470               REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   327

TABLE 471               REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)               328

TABLE 472               REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   328

TABLE 473               REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   328

TABLE 474               REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS,

BY TYPE, 2023–2030 (USD MILLION)    329

TABLE 475               REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)             329

TABLE 476               REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2030 (USD MILLION)            330

TABLE 477               REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   330

TABLE 478               REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)         331

TABLE 479               REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   331

TABLE 480               REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,

2023–2030 (USD MILLION)   331

TABLE 481               REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS,

BY TYPE, 2023–2030 (USD MILLION)    332

TABLE 482               REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)             332

TABLE 483               REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   333

TABLE 484               AFRICA: KEY MACROECONOMIC INDICATORS         334

TABLE 485               AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,

2023–2030 (USD MILLION)   334

TABLE 486               AFRICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 335

TABLE 487               AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,

2023–2030 (USD MILLION)   335

TABLE 488               AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2030 (USD MILLION)               335

TABLE 489               AFRICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)   336

TABLE 490               AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)   336

TABLE 491               AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,

2023–2030 (USD MILLION)   337

TABLE 492               OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET        338

TABLE 493               CLINICAL TRIAL SUPPLIES MARKET: DEGREE OF COMPETITION          342

TABLE 494               CLINICAL TRIALS SUPPLIES MARKET: REGION FOOTPRINT                 346

TABLE 495               CLINICAL TRIAL SUPPLIES MARKET: SERVICE FOOTPRINT                 347

TABLE 496               CLINICAL TRIAL SUPPLIES MARKET: TYPE FOOTPRINT                 348

TABLE 497               CLINICAL TRIAL SUPPLIES MARKET: END-USER FOOTPRINT                 349

TABLE 498               CLINICAL TRIAL SUPPLIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES    351

TABLE 499               CLINICAL TRIAL SUPPLIES MARKET: COMPETITIVE BENCHMARKING

OF KEY STARTUPS/SMES        352

TABLE 500               CLINICAL TRIAL SUPPLIES MARKET: DEALS, JANUARY 2021–MARCH 2025          355

TABLE 501               CLINICAL TRIAL SUPPLIES MARKET: EXPANSIONS, JANUARY 2021–MARCH 2025               356

TABLE 502               THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW                 357

TABLE 503               THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED                 358

TABLE 504               THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES,

JANUARY 2021–MARCH 2025                359

TABLE 505               THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–MARCH 2025          359

TABLE 506               THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–MARCH 2025               360

TABLE 507               NOVO HOLDINGS A/S: COMPANY OVERVIEW          361

TABLE 508               NOVO HOLDINGS A/S: SERVICES OFFERED            362

TABLE 509               NOVO HOLDINGS A/S: DEALS, JANUARY 2021–MARCH 2025                 363

TABLE 510               NOVO HOLDINGS A/S: EXPANSIONS, JANUARY 2021–MARCH 2025       364

TABLE 511               UNITED PARCEL SERVICE OF AMERICA, INC.: COMPANY OVERVIEW                366

TABLE 512               UNITED PARCEL SERVICE OF AMERICA, INC.: SERVICES OFFERED 366

TABLE 513               EUROFINS SCIENTIFIC: COMPANY OVERVIEW         369

TABLE 514               EUROFINS SCIENTIFIC: SERVICES OFFERED           370

TABLE 515               PIRAMAL PHARMA LIMITED: COMPANY OVERVIEW 372

TABLE 516               PIRAMAL PHARMA LIMITED: SERVICES OFFERED  373

TABLE 517               IQVIA: COMPANY OVERVIEW   375

TABLE 518               IQVIA: SERVICES OFFERED      377

TABLE 519               ICON PLC: COMPANY OVERVIEW             378

TABLE 520               ICON PLC: SERVICES OFFERED               379

TABLE 521               ICON PLC: DEALS, JANUARY 2021–MARCH 2025  380

TABLE 522               LONZA: COMPANY OVERVIEW 381

TABLE 523               LONZA: SERVICES OFFERED   382

TABLE 524               LONZA: DEALS, JANUARY 2021–MARCH 2025      382

TABLE 525               UNIPHAR GROUP PLC: COMPANY OVERVIEW          383

TABLE 526               UNIPHAR GROUP PLC: SERVICES OFFERED            384

TABLE 527               ALMAC GROUP: COMPANY OVERVIEW    385

TABLE 528               ALMAC GROUP: SERVICES OFFERED      385

TABLE 529               ALMAC GROUP: EXPANSIONS, JANUARY 2021–MARCH 2025                 386

TABLE 530               SHARP SERVICES, LLC: COMPANY OVERVIEW        387

TABLE 531               SHARP SERVICES, LLC: SERVICES OFFERED          387

TABLE 532               PCI PHARMA SERVICES: COMPANY OVERVIEW       389

TABLE 533               PCI PHARMA SERVICES: SERVICES OFFERED         389

TABLE 534               PCI PHARMA SERVICES: EXPANSIONS, JANUARY 2021–MARCH 2025          390

TABLE 535               PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW                391

TABLE 536               PAREXEL INTERNATIONAL (MA) CORPORATION.: SERVICES OFFERED 391

TABLE 537               PAREXEL INTERNATIONAL (MA) CORPORATION: DEALS,

JANUARY 2021–MARCH 2025                392

TABLE 538               BIOCAIR: COMPANY OVERVIEW               393

TABLE 539               BIOCAIR: SERVICES OFFERED 393

TABLE 540               CENCORA, INC.: COMPANY OVERVIEW    394

TABLE 541               CLINIGEN LIMITED: COMPANY OVERVIEW               395

TABLE 542               KLIFO: COMPANY OVERVIEW  396

TABLE 543               IPS PHARMA: COMPANY OVERVIEW        397

TABLE 544               COREX LOGISTICS LIMITED: COMPANY OVERVIEW 398

TABLE 545               OCT GROUP LLC: COMPANY OVERVIEW  399

TABLE 546               MYONEX: COMPANY OVERVIEW              400

TABLE 547               INCEPTUA GROUP: COMPANY OVERVIEW                401

TABLE 548               ANCILLARE, LP: COMPANY OVERVIEW    402

TABLE 549               ADALLEN PHARMA: COMPANY OVERVIEW              403

TABLE 550               CLINICAL SERVICES INTERNATIONAL (CSI): COMPANY OVERVIEW                404

TABLE 551               NUVISAN GMBH: COMPANY OVERVIEW  405

TABLE 552               AENOVA HOLDING GMBH: COMPANY OVERVIEW   406

LIST OF FIGURES

FIGURE 1 MARKET SEGMENTATION & GEOGRAPHIC SPREAD                39

FIGURE 2 CLINICAL TRIAL SUPPLIES MARKET: RESEARCH DESIGN       43

FIGURE 3 CLINICAL TRIAL SUPPLIES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS             45

FIGURE 4 CLINICAL TRIAL SUPPLIES MARKET SIZE ESTIMATION

(SUPPLY-SIDE ANALYSIS), 2024              46

FIGURE 5 CLINICAL TRIAL SUPPLIES MARKET ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024 47

FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2024)        47

FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES           48

FIGURE 8 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH               49

FIGURE 9 CLINICAL TRIAL SUPPLIES MARKET: CAGR PROJECTIONS      50

FIGURE 10               DATA TRIANGULATION METHODOLOGY  52

FIGURE 11               CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)         55

FIGURE 12               CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,

2025 VS. 2030 (USD MILLION)               56

FIGURE 13               CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2025 VS. 2030 (USD MILLION)               57

FIGURE 14               CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2025 VS. 2030 (USD MILLION)               57

FIGURE 15               CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)               58

FIGURE 16               GEOGRAPHIC SNAPSHOT OF CLINICAL TRIAL SUPPLIES MARKET, 2025−2030            59

FIGURE 17               GROWTH IN CLINICAL TRIALS AND DRUG DEVELOPMENT TO PROPEL MARKET    60

FIGURE 18               SMALL MOLECULES AND BIOLOGICS TO ACCOUNT FOR LARGEST MARKET SHARE IN NORTH AMERICA      61

FIGURE 19               SMALL MOLECULES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD    61

FIGURE 20               CHINA PROJECTED TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD  62

FIGURE 21               CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES      64

FIGURE 22               NUMBER OF CLINICAL TRIALS PER YEAR, 2004–2024                 65

FIGURE 23               CLINICAL TRIAL SUPPLIES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES  69

FIGURE 24               CLINICAL TRIAL SUPPLIES MARKET: VALUE CHAIN ANALYSIS                 70

FIGURE 25               CLINICAL TRIAL SUPPLIES MARKET: ECOSYSTEM ANALYSIS                 72

FIGURE 26               CLINICAL TRIAL SUPPLIES MARKET: PORTER’S FIVE FORCES ANALYSIS 86

FIGURE 27               INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER                88

FIGURE 28               KEY BUYING CRITERIA FOR CLINICAL TRIAL SUPPLIES, BY END USER                89

FIGURE 29               IMPACT OF AI ON CLINICAL TRIAL SUPPLIES ECOSYSTEM                 91

FIGURE 30               NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT               223

FIGURE 31               ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT                 269

FIGURE 32               REVENUE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET, 2020–2024 (USD MILLION)   340

FIGURE 33               MARKET SHARE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET (2024)            341

FIGURE 34               CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024             344

FIGURE 35               CLINICAL TRIAL SUPPLIES MARKET: COMPANY FOOTPRINT                 345

FIGURE 36               CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024          350

FIGURE 37               EV/EBITDA OF KEY VENDORS 353

FIGURE 38               YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA

OF KEY VENDORS   353

FIGURE 39               CLINICAL TRIAL SUPPLIES MARKET: BRAND/SERVICE COMPARATIVE ANALYSIS         354

FIGURE 40               THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT                 358

FIGURE 41               NOVO HOLDINGS A/S: COMPANY SNAPSHOT         362

FIGURE 42               EUROFINS SCIENTIFIC: COMPANY SNAPSHOT        370

FIGURE 43               PIRAMAL PHARMA LIMITED: COMPANY SNAPSHOT                 373

FIGURE 44               IQVIA: COMPANY SNAPSHOT   376

FIGURE 45               ICON PLC: COMPANY SNAPSHOT             378

FIGURE 46               LONZA: COMPANY SNAPSHOT 381

FIGURE 47               UNIPHAR GROUP PLC: COMPANY SNAPSHOT         383

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧